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SUMMARY

Microglia are a key immune-competent cell type that
respond to environmental and physiological changes
during ischemic stroke. However, the molecular
mechanisms controlling post-ischemic microglia activity are unclear. Understanding these mechanisms
may ultimately reduce disease burden and allow
the manipulation of microglia responses to shape
the outcomes of stroke. Here, we report that, after
experimentally induced stroke, ZEB1 is highly expressed in ipsilateral cerebral hemisphere, where it
is upregulated mainly in microglia. Using a conditional transgenic mouse, we found that ZEB1 upregulation in microglia regulates immune responses
in the CNS and alleviates brain injury after ischemic
stroke. Our data indicate that ZEB1 overexpression
mediates microglia responses and, in turn, inhibits
the production of astrocytic CXCL1 through the
TGF-b1-dependent pathway. Reduced CXCL1 leads
to a decline in neutrophil infiltration into the brain,
thereby reducing CNS inflammation. Our results
demonstrate the importance of ZEB1 in microgliaorchestrated neuroinflammation and suggest a
potential means for reducing stroke-induced neurological injury.
INTRODUCTION
Stroke is a major cause of adult disability and death worldwide (Iadecola and Anrather, 2011; Macrez et al., 2011).
Inflammation and lymphocyte invasion occur within minutes
to a few hours after acute ischemic stroke and are known
as key contributors to brain injury (Benakis et al., 2015; Chamorro et al., 2016; Kleinschnitz et al., 2013). Therapeutic interventions that involve manipulating the immune system
are being explored in patients with ischemic stroke (Fu
et al., 2014, 2015). However, our understanding of immuno-

modulation is still in its infancy, largely because clinical trials
of regulatory drugs have not been generally successful. Also,
limited knowledge about the molecular mechanisms underlying neuroinflammation has impeded researchers from better
understanding the profound role that inflammation plays in
stroke and its aftermath.
Microglia are brain-resident immune cells that refine synaptic
networks, promote cellular apoptosis, remove apoptotic cell
corpses, position neurons within the developing mammalian barrel cortices, and govern the precise secretion of growth factors
for neuronal survival (Parkhurst et al., 2013; Stevens et al.,
2007). Depending on the timing and disease stage, microglia
also contribute to post-ischemic stroke brain injury or are
involved in repairing it. However, the molecular machinery governing post-ischemic microglia activity is complex and far from
understood (Hu et al., 2015).
Zinc finger E-box binding homeobox 1 (ZEB1) is a member of
the zinc finger-homeodomain transcription factor family that
modulates cell differentiation and specific cellular functions in
multiple tissues (Funahashi et al., 1993; Hasuwa et al., 2013).
In solid tumors, ZEB1 can repress E-cadherin, induce epithelial-mesenchymal transition (EMT), induce chemo- and radioresistant phenotypes, and promote the generation of cancer
stem cells (Chaffer et al., 2013; Zhang et al., 2014). ZEB1 also
participates in regulating the development of the immune system
(Arnold et al., 2012). A previous study reported that ZEB1 overexpression represents a protective response to brain ischemia
(Bui et al., 2009), but the cellular and molecular mechanisms of
ZEB1 that underlie this protective response against ischemic
stroke remain obscure.
Here, we report on the development of a genetic system for
targeting microglia that illuminates their pathologic activities during ischemic stroke more specifically and directly than previously
possible (Goldmann et al., 2013). To genetically manipulate microglia, we exploit their longevity and self-renewal properties
and the expression of Cre recombinase driven by the CX3CR1
promoter. Using this modified genetic system, we measured
ZEB1 expression after brain ischemia and determined the
impact of microglial ZEB1 expression on CNS inflammation
and tissue injury after stroke. The net effect of microglial
ZEB1 signaling is probably determined by moderating the
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Figure 1. ZEB1 Expression Is Dramatically Elevated in Microglia after Stroke
(A) ZEB1 protein levels were examined from the contralateral cortex (C) and ischemic ipsilateral cortex (I) of mice that underwent tMCAO after 24 hr of reperfusion.
Western blots were analyzed with ImageJ software and normalized to GAPDH expression. Left panel shows representative TTC staining of brain sections from
tMCAO mice.
(B) ZEB1 transcription level in primary neurons, astrocytes, and microglia after OGD for 24 hr.
(C) ZEB1 expression in primary microglia undergoing OGD for 0, 3, 6, 12, or 24 hr followed by exposure to a normal oxygen concentration level for 24 hr.
(D) Quantitation and statistical evaluation of data in (C). Ordered bars correspond to ordered lanes in (C).
(E) qPCR analysis of ZEB1 expression after OGD for 0, 3, 6, 12, or 24 hr and after normal oxygen concentration for 24 hr.
(F) Representative immunohistochemical staining for microglia and ZEB1 from contralateral (Contra) and ipsilateral (Ipsi) regions of ischemic penumbra of brain
tissue after tMCAO. Rightmost panel shows inset box to left at a higher magnification. Intensity of ZEB1 immunofluorescence was quantified using ImageJ. Scale
bars, 20 mm.
Data indicate means ± SEM (n = 6 per group). *p < 0.05.

inflammatory milieu after ischemic stroke. We propose that
ZEB1 is a key regulator of microglia responses in the events
after ischemic stroke and may be critically involved in
neuroinflammation.
RESULTS
Microglial ZEB1 Is Upregulated after Acute Brain
Ischemia
To examine the specific molecular mechanisms of inflammation
in the ischemic brain, we explored possible molecular factors
that might contribute to the inflammatory response soon after
ischemic stroke. We developed a mouse model of ischemic
stroke by adapting the Longa method (Li et al., 2016). 24 hr after

the induction of transient middle cerebral artery occlusion
(tMCAO), we removed cortical samples from the contralateral
side and the penumbra of the mouse brains and then examined
ZEB1 expression using western blot. As Figure 1A depicts, ZEB1
expression was higher in the ischemic hemisphere compared
the contralateral hemisphere.
Next, to examine which cell type exhibited ZEB1 upregulation
after tMCAO, we isolated and cultured microglia, astrocytes, and
neurons from brains of neonatal mice (Dagda and Rice, 2017; Li
et al., 2016). We then subjected these cells to oxygen-glucose
deprivation (OGD; 1% oxygen and 99% nitrogen). qPCR analysis
showed that, although microglia and neurons exhibited elevated
ZEB1 expression, microglia displayed greater ZEB1 expression
(Figure 1B). In primary microglia subjected to OGD at several
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time points, we found that ZEB1 expression progressively
increased with longer periods of OGD, and then ZEB1 mRNA
and protein levels returned to baseline levels after exposure
to normal oxygen concentrations for 24 hr (Figures 1C–1E).
Immunohistochemical staining of brain sections corroborated
the qPCR results, showing that ZEB1 staining in microglia was
more intense and concentrated in the ipsilateral hemisphere
compared to the contralateral hemisphere (Figure 1F). These
data suggest that ZEB1 expression is upregulated in the
ischemic penumbra and that activated microglia are the main
source of ZEB1 there.
Characterization of ZEB1-Knockdown
and ZEB1-Transgenic Mice
To investigate the involvement of microglial ZEB1 in ischemic
stroke, we examined mice that expressed lower levels of microglial ZEB1 (knockdown [KD]; ZEB1-KD) and mice that overexpressed microglial ZEB1 (transgenic [TG]; ZEB1-TG). First, we
generated Zeb1-TG mice and Zeb1-KD mice, which harbor,
respectively, a stop element of the Zeb1 gene flanked by a
loxP site or exon 4 of the Zeb1 gene flanked by a loxP site (Figure 2A). Mice carrying loxP-flanked Zeb1 alleles were crossed
with mice expressing CX3CR1CreER (Figure 2B). ZEB1-TG mice
were generated by crossing CX3CR1CreER mice and Zeb1-TG
mice, and ZEB1-KD mice were generated by crossing
CX3CR1CreER mice and Zeb1-KD mice.
We first assessed microglial ZEB1 expression in ZEB1-KD
mice and found that both ZEB1 mRNA and protein levels were
downregulated. ZEB1 expression in splenic monocytes, however, was not downregulated. Unlike in ZEB1-KD mice, microglial ZEB1 expression in ZEB1-TG mice was upregulated
compared to their wild-type (WT) littermates (Figures 2C and
2D). ZEB1-KD and ZEB1-TG mice developed normally,
showing no obvious signs of neurological disease, infertility,
or behavioral abnormalities. There were also no differences in
either gross brain structure or the number of astrocytes, microglia, and neurons (Figures S1A–S1C). Flow-cytometric analysis
showed that differential expression of microglial ZEB1 did not
affect the number of peripheral immune cell subtypes (Figures
S1D and S1E).
Targeted Overexpression of Microglial ZEB1 Reduces
Acute Ischemic Brain Injury
After induction of tMCAO, we first tested the neurological function of WT, ZEB1-TG, and ZEB1-KD mice. ZEB1-KD mice had
more severe neurological deficits than WT mice, and ZEB1-TG
mice were less impaired in the components of the modified
Neurological Severity Score (mNSS), foot-fault test, and
corner-turning test (Figures 2E, 2G, and 2H) after tMCAO. Performance in the adhesive-removal test was statistically indistinguishable across the three groups of mice (Figure 2F). Analysis
of 2,3,5-triphenyltetrazolium chloride (TTC) staining (Figure 2I)
supported the behavioral results. After reperfusion, ZEB1-KD
mice had significantly larger infarcts than WT mice, whereas
ZEB1-TG mice had smaller infarcts. The protective impact of microglial ZEB1 on brain injury may persist through the acute stage
to late stages of stroke (Figure S2). Examination of blood-brain
barrier (BBB) permeability revealed that the ZEB1-TG mice had
3576 Cell Reports 22, 3574–3586, March 27, 2018

significantly less Evans blue extravasation compared to WT
mice, and as expected, ZEB1-KD mice had significantly more
extravasation (Figure 2J, right panel). Since cell apoptosis is a
well-known hallmark following stroke, we used a propidium iodide (PI)-annexin V kit to test for apoptotic cells after tMCAO.
In ZEB1-TG mice, fewer cells in the ischemic hemisphere underwent apoptosis, but in ZEB1-KD mice, more cells underwent
apoptosis than in WT mice (Figure 2K). Also, reactive oxygen
species in the ZEB1-TG group were reduced compared to those
in the WT group (Figure S3). Taken together, these results indicate that selective overexpression of microglial ZEB1 plays a
protective role after ischemic stroke.
ZEB1 Affects Microglia Morphology and Activity after
tMCAO
Since microglia are key immune cells that can respond quickly to
environmental changes in the brain, we focused specifically on
microglia and investigated ZEB1-mediated microglia response.
First, we performed detailed quantitative morphometric analysis
of Iba-1-positive microglia in the hippocampus, neocortex, and
cerebellum of transgenic mice and WT mice under normal conditions. As demonstrated in three-dimensional reconstructions
of confocal z stacks of imaged Iba-1-positive microglia,
ZEB1-KD microglia showed fewer sparsely spaced processes
compared to microglia from WT mice, and ZEB1-TG microglia
showed a distinct arborization pattern of finely delineated processes (Figure 3A, schematic). Corroborating this observation,
Sholl analysis revealed that the processes of ZEB1-TG microglia
were more complex than those of WT microglia and that the processes of ZEB1-KD microglia were less complex (Figure 3A,
graph on right).
We next counted the numbers of Iba-1-positive microglia in
WT, ZEB1-TG, and ZEB1-KD mice after tMCAO. While we found
no difference across the three groups in the penumbra region
(Figures 3B and 3C). The summed lengths of microglial processes and the percentages of ameboid microglia across the
three groups were similar (Figures 3D and 3E). We also assessed
the degree of activation of microglia by quantifying microglia
shapes using image analysis of 2D somatic projections. Shape
parameters were calculated based on measuring maximum
length (L) and projection area (A) of individual imaged microglia.
When microglia became activated, the somatic shape index
(L/A) decreased. However, the L/A ratio in WT mice was larger
than in ZEB1-TG mice and smaller than in ZEB1-KD mice (Figures 3F and 3G).
Lastly, we assessed the apoptosis and proliferation rate of
microglia using a (PI)-annexin V kit and Ki-67. In this experiment,
microglia was referred to as CD11b+CD45low. Examination of the
extent of microglial apoptosis and proliferation revealed no differences between WT, ZEB1-TG, and ZEB1-KD mice (Figures
3H and 3I). Overall, these data indicate that, after ischemic
stroke, ZEB1 is associated with microglia having a more ramified
morphology and a less reactive phenotype.
ZEB1 Expression Is Associated with a Distinctive
Microglial Gene Expression Profile
To further investigate whether ZEB1 affects microglia function
after ischemic stroke, we performed mRNA microarray (Agilent

Figure 2. Microglia-Specific ZEB1 Upregulation Reduces Neurovascular Injury after Ischemia
(A) Gene strategy for preparing Zeb1-TG and Zeb1-KD mice.
(B) Breeding scheme for CX3CR1Cre ER mice crossed with Zeb1-TG or Zeb1-KD mice. The offspring for the former are denoted as ZEB1-TG, in which ZEB1 is
overexpressed in microglia; the latter are denoted as ZEB1-KD mice, in which ZEB1 is downregulated in microglia.
(C) Relative expression of ZEB1 mRNA in microglia and splenic monocytes from ZEB1-TG, ZEB1-KD mice, and wild-type (WT) mice, assessed using qPCR.
(D) ZEB1 expression was detected in microglia and monocytes by western blot.
(E–H) 24 hr after tMCAO, we evaluated neurological deficits of in WT, ZEB1-TG, and ZEB1-KD mice after tMCAO using the mNSS (E), adhesive-removal test (F),
foot-fault test (G), and corner-turning test (H) in WT, ZEB1-TG, and ZEB1-KD mice.
(I) TTC staining was used to evaluate infarct volumes in the three groups 24 hr after tMCAO. After staining, undamaged tissue appears deep red, and infarcted
tissue remains white. Dashed lines encompass the estimate of infarct at one rostro-caudal level. Infarct volumes were quantified using Image-Pro-Plus v.5.0
software (right panel).
(J) Evans blue extravasation in WT, ZEB1-TG, and ZEB1-KD mice. Top row: dorsal view of whole brain; bottom row: representative rostro-caudal levels of Evansblue-stained tissue.
(K) 24 hr after tMCAO, the number of apoptotic cells from brains of the three groups were assessed using an annexin-PI kit and fluorescence-activated cell sorting
(FACS).
*p < 0.05 (ZEB1-TG versus WT); #p < 0.05 (ZEB1-KD versus WT). Data indicate mean ± SEM (n = 6 per group). See also Figures S1, S2, and S3.

Technologies) analyses, which generated microglia-specific
gene expression profiles. ZEB1 affected the expression not of
single genes or small gene clusters but thousands of genes,
leading to what appears to be a ‘‘complete reprogramming’’ of
microglia. Microarray gene profiles clearly distinguished microglia from WT, ZEB1-TG, and ZEB1-KD mice (Figure 4A). Using

a more than 2-fold change threshold, we observed that ZEB1
significantly influences gene expression in microglia.
Next, we performed a Gene Ontology analysis of the differentially expressed genes from all comparisons, using the Database
for Annotation, Visualization, and Integrated Discovery (DAVID) to
gain an overview about the nature of gene and potential shared
Cell Reports 22, 3574–3586, March 27, 2018 3577

Figure 3. Effects of ZEB1 Expression on Microglial Morphology
Morphological correlates of microglia activation assessed with an antibody against anti-Iba-1, a microglial marker.
(A) Detailed morphology of microglia in WT mice under normal conditions. The three left panels show Imaris (Bitplane)-based three-dimensional reconstructions
of representative microglia in WT, ZEB1-TG, and ZEB1-KD mice. Middle: schematic diagram of a three-dimensional Sholl grid of concentric spheres centered on
the geometric center of the microglia cell somata (red cross). Branch crossings along the spherical grid allowed us to quantify the number and branch lengths of
three-dimensionally reconstructed microglial processes between consecutive spheres. This provides an estimate of the degree of microglial process complexity.
The graphs on the right show the Sholl quantitation of microglial processes. IS, segment interactions.
(B) Representative confocal images of immunohistochemical staining of microglia in the penumbra of WT, ZEB1-TG, and ZEB1-KD mice. Scale bar, 50 mm.
(C) Iba-1-positive cells were counted in the penumbra of immunohistochemically stained brain sections from WT, ZEB1-TG, and ZEB1-KD mice.
(D) Total process lengths of confocal images of immunostained microglia were analyzed by Image J.
(E) Percentage of ameboid microglia in the penumbra of WT, ZEB1-TG, and ZEB1-KD mice.
(F) Shape analyses of two-dimensional somatic projections based on maximum length (L) and projection area (A) in confocal images of Iba-1-immunostained
microglia (right) using ImageJ. The somatic shape index (L/A ratio) increases in rod-shaped somata.
(G) Quantitation of microglial somata L, A, and the L/A ratio.
(H) Apoptosis flow-cytometric analyses of microglia after tMCAO.
(I) Proliferation of microglia in WT, ZEB1-TG, and ZEB1-KD mice after tMCAO, as revealed by FACS analysis of Ki-67-stained cells.
*p < 0.05 (ZEB1-TG versus WT); #p < 0.05 (ZEB1-KD versus WT). Data indicate means ± SEM. n = 6 per group.

pathways (Huang et al., 2009). Here, we listed the top 10 enriched
clusters in the comparison of WT/ZEB1-TG (Figure 4B) with WT/
ZEB1-KD (Figure 4C). Interestingly, several of these enriched
terms were shared between the different pairwise comparisons
including immune system process, innate immune response,
and cellular response to interferon (IFN)-b which are involved in
inflammation and cell response. Under normal (non-tMCAO) conditions, these Gene Ontology terms were not involved in the comparison of WT/ZEB1-TG with WT/ZEB1-KD (Figure S4). Therefore, ZEB1 is very important for microglia plasticity. Microglial
ZEB1 may play a role in monitoring the local environment and
regulating the immune response after ischemic stroke.
3578 Cell Reports 22, 3574–3586, March 27, 2018

Neutrophil Infiltration Is Attenuated with Microglial
ZEB1 Overexpression
To determine the potential impact of microglia ZEB1 on the immune response after tMCAO, we measured the accumulation of
leukocytes in the brains of WT, ZEB1-TG, and ZEB1-KD mice
after tMCAO by using flow cytometry. The gating strategy is
shown in Figure 5A. 24 hr post-tMCAO reperfusion, we found
no difference between WT, ZEB1-TG, and ZEB1-KD mice in
the numbers of microglia, CD4+T cells, CD8+ T cells, natural
killer (NK) cells, B cells, or macrophages; Similarly, CD86-positive and CD206-postive microglia counts did not differ (Figure 5B). In contrast, ZEB1-TG mice had decreased

Figure 4. Effect of ZEB1 Expression on the
Molecular Profiles of Microglia
Microglia were isolated from the brains of WT,
ZEB1-TG, and ZEB1-KD mice by using a CX3CR1
selection kit.
(A) Heatmap of gene profiles of microglia in WT,
ZEB1-TG, and ZEB1-KD mice.
(B) The ten most enriched clusters in the comparisons of WT and ZEB1-TG mice, including the
log10 (P value), are shown.
(C) The 10 most enriched clusters in the comparisons of WT and ZEB1-KD mice, including the
log10 (P value), are shown. (n = 2 per group).
See also Figure S4.

accumulations of neutrophils in the brain, while ZEB1-KD mice
had increased neutrophil infiltration compared with WT mice
(Figures 5B and 5D). These significant differences persisted
up to 3 days after tMCAO (Figure 5E). Interestingly, the spleens
of ZEB1-TG mice exhibited increased numbers of neutrophils
but no increase of any other leukocyte subtype. The spleens
of ZEB1-KD and WT mice had comparable numbers of neutrophils (Figures 5C and 5F). We also analyzed monocytes after
tMCAO, since monocytes infiltrate the brain in large quantities
during acute ischemic stroke (Kriz and Lalancette-Hébert,
2009). The number and phenotype of monocytes in the three
groups did not differ (Figure S5). When depleting neutrophils
in ZEB1-TG and ZEB1-KD mice, the clinical score and infarct
volumes were similar to those of WT mice (Figure S6). These results suggest that overexpression of microglial ZEB1 may lead
to a reduction in the accumulation of neutrophils in the ischemic
brain.
ZEB1 Enhancement Decreases Neutrophil
Chemoattractant C-X-C Motif Ligand 1
We showed that neutrophils rapidly infiltrate the CNS after
tMCAO, contributing to inflammation and aggravating brain
damage. This selective migration of neutrophils depends on
many molecules and chemokines that emerge after ischemic
stroke (Murikinati et al., 2010). We first examined neutrophil-attracting chemokines and found that mRNA levels of C-X-C motif
ligand 1 (CXCL1)—a chemokine that mainly recruits neutrophils—dramatically decline only in the ZEB1-TG mice after
tMCAO (Figure 6A). Given that astrocytes and microglia are
the first cells that respond in ischemic stroke, we reasoned
that one of these might be the major source of brain CXCL1.
Double-immunofluorescent staining of brain sections from WT
mice with anti-Iba-1 and anti-CXCL1 (for microglia), anti-glial

fibrillary acidic protein (GFAP) and antiCXCL1 (for astrocytes), and anti-NeuN
and anti-CXCL1 (for neurons) indicated
that astrocytes are the source of brain
CXCL1 after tMCAO (Figure 6B). In
ZEB1-TG mice, CXCL1-GFAP doubleimmunofluorescent staining showed, as
expected, that CXCL1 staining intensity
was reduced compared to that in WT
mice (Figure 6C, D). These results suggest that microglia-derived ZEB1 can affect the expression of
CXCL1 in the ischemic brain.
Transmigration of Spatially Isolated Neutrophils
Is Reduced in Astrocyte-Microglia Co-cultures
from ZEB1-TG Mice
Since astrocytes are the major source of CXCL1, we investigated
whether astrocytes from WT mice and ZEB1-TG mice differed in
their ability to induce neutrophil migration. Using purified astrocytes from WT and ZEB1-TG mice, we exposed them to OGD
for 12 hr and then cultured them for 4 hr in a Transwell system
with purified neutrophils separated by a Transwell membrane
(neutrophils in the upper chamber) (Figure 7A); the purity of cells
is shown in Figure S7. The proportions of neutrophils that had
migrated into the lower Transwell chamber were not significantly
different between cultures of WT and ZEB1-TG astrocytes (Figure 7B, left). ELISA analysis for CXCL1 in the supernatants of
cultured astrocytes also failed to detect a difference in the concentration of CXCL1 between the two groups (Figure 7B, right).
Thus, we hypothesized that microglia may play a role in the
migration of these neutrophils in situ.
Microglia and astrocytes from WT and ZEB1-TG mice were
co-cultured, and again, using the same Transwell system, we
calculated a neutrophil migration index. After 12 hr, the migration
of neutrophils from ZEB1-TG mice in the mixed-glial cultures
was dramatically reduced compared to neutrophils from WT
mixed-glial cell cultures (Figure 7C, left); ELISA analysis also
showed significantly reduced CXCL1 in the supernatant of
ZEB1-TG mixed-glial cell cultures (Figure 7C, right).
To assess whether cytokines produced by microglia might
influence CXCL1 content in astrocytes, we used a conditioned
medium system, immunofluorescent staining, and flow cytometry
(Figure 7D). After 12 hr, we measured astrocyte-secreted CXCL1
Cell Reports 22, 3574–3586, March 27, 2018 3579

Figure 5. Neutrophil Infiltration Is Attenuated with Microglial ZEB1 Overexpression
(A) Gating strategy for leukocytes and subtypes and microglia isolated from the brain after tMCAO. Fluorescence minus one (FMO) controls were used in the
gating strategy.
(B) Counts of macrophages, neutrophils, CD4+ T cells, CD8+ T cells, NK cells, B cells and microglia, and CD86-expressing and CD206-expressing microglia in
brains of WT, ZEB1-TG, and ZEB1-KD mice 24 hr after tMCAO. Data represent absolute cell numbers per brain.
(C) Counts of splenocytes in WT, ZEB1-TG, and ZEB1-KD mice 24 hr after tMCAO.
(D) Immunofluorescent staining of brain sections shows representative density of neutrophils in peri-infarct areas of WT, ZEB1-TG, and ZEB1-KD mice 24 hr after
tMCAO. Scale bar, 20 mm.
(E and F) Neutrophils were quantified by using flow cytometry of brain (E) and spleen (F) cells of WT, ZEB1-TG, and ZEB1-KD mice 1, 3, and 7 days after tMCAO.
Data indicate means ± SEM. n = 6 per group. *p < 0.05 WT versus ZEB1-TG mice; #p < 0.05 WT versus ZEB1-KD mice. See also Figures S5 and S6.

in conditioned medium from WT or ZEB1-TG cultures (Figure 7E)
and observed that the fluorescence intensity and percentage of
CXCL1 were significantly reduced in astrocytes from ZEB1-TG
microglia-conditioned medium. Thus, microglia appear to engage
in ‘‘crosstalk’’ with astrocytes, inhibiting the production of CXCL1
by astrocytes. In addition, microglial ZEB1 overexpression shows
a more potent inhibitory effect during the process.
We next used qPCR and the neutrophil Transwell system to
investigate which microglial cytokine influences CXCL1 production in astrocytes. Since WT and ZEB1-TG microglia differed in
their content of several cytokines, we sequentially applied antibodies of tumor necrosis factor a (TNF-a), interleukin (IL)-4,
IL-6, or transforming growth factor b1 (TGF-b1) to block the action of each cytokine in the Transwell experiment (Figure 7F).
Only by blocking TGF-b1 did the neutrophil migration indexes
in the WT and ZEB1-TG groups become equal (Figure 7G). Presumably, then, in ZEB1-TG mice, microglia can inhibit astrocytic
CXCL1 production by secreting TGF-b1. Astrocytes cultured
with ZEB1-TG microglia-conditioned medium produced more
p-SMAD2/3, as assessed by both western blot and flow-cytometric analyses (Figure S8), further substantiating the hypothesis
that microglia can communicate with astrocytes through the
TGF-b1 pathway and inhibit the latter’s production of CXCL1;
ZEB1 overexpression facilitates this.
To investigate the mechanism of how ZEB1 regulates TGF-b1
in microglia, we conducted a series of experiments in a microglia
3580 Cell Reports 22, 3574–3586, March 27, 2018

cell line, BV2 cells. First, BV2 cells were transfected with the
ZEB1 expression or control plasmid, and the mRNA of TGF-b1
was tested by qPCR. The mRNA was increased after the transfection of ZEB1 expression plasmid (Figure 7H). Then, we performed the luciferase assays to elucidate the molecular mechanism by which ZEB1 regulates TGF-b1 transcription. As shown in
(Figure 7I), the luciferase assay indicated that ZEB1 overexpression increases the promoter activity of the TGF-b1-p-1.8k reporter up to 3-fold, relative to control BV2 cells. Next, we conducted chromatin immunoprecipitation (ChIP) assays to detect
whether ZEB1 could directly bind to the E2-box. The assays revealed that ZEB1 could bind to the TGF-b1 promoter under basal
conditions in an E2-box-dependent manner. Importantly, quantitative ChIP assays indicated that ZEB1 overexpression results in
an increase in its binding to the area of E2-box1, E2-box2. However, the recruitment of ZEB1 to E2-box3 was less evident (Figure 7J). These observations indicate that ZEB1 binds directly
to the endogenous TGF-b1 promoter at the positions 643/
637 and 917/ 911, resulting in the transcriptional activation
of TGF-b1.
Blockade of TGF-BRII in Astrocytes Abolishes the
Protective Effect in ZEB1-TG Mice
Microglial TGF-b1 production was measured 1, 3, and 7 days after
tMCAO and reperfusion. In ZEB1-TG mice, microglial TGF-b1 production was greater than WT mice (Figures 8A and 8B), especially

Figure 6. Microglia-Targeted ZEB1 Expression Reduces Neutrophil Chemoattractant CXCL1 Derived from Astrocytes
(A) qPCR analysis of chemokines related to the infiltrated neutrophils in WT and ZEB1-TG mice after tMCAO.
(B) Confocal microscopy images of WT brain sections double-immunofluorescent stained for Iba-1 and CXCL1, for GFAP and CXCL1, and for NeuN and CXCL1.
Scale bar, 10 mm.
(C) Similar immunohistochemical experiments with WT and ZEB1-TG mice, showing robust spatial overlap of GFAP and CXCL1 immunostaining after tMCAO.
Boxes in the third column of panels are shown in higher magnification in the adjacent panels. Reference boxes in the rightmost panels indicate area over which 2.5
dimensional (2.5D) staining intensity analysis of CXCL1 was done. Scale bar, 50 mm.
(D) Results of a 2.5D intensity analysis of CXCL1 immunostaining. Data are means ± SEM. *p < 0.05.

1 day after tMCAO (Figures 8C and 8D). To determine whether microglia of ZEB1-TG mice secrete more TGF-b1 and influence
CXCL1 content in astrocytes, we manufactured an adeno-associated virus (AAV) harboring a GFAP promoter and encoding region
for TGF-BRII, a TGF receptor (Figure 8E). AAV-shTGFBRII (6 3 109
IU) or control AAV was injected into the brains of WT mice. Three
weeks after transfection, the mice underwent tMCAO. Twentyfour hours later, their brains were removed, and cells were
analyzed by flow-cytometric analysis. Histogram plots showed
that the number of TGF-BRII receptors in astrocytes were dramatically smaller in the AAV-shTGFBRII-transfected mice compared
with those in AAV-control mice (Figure 8F).
We next examined the number of neutrophils in the
brains and spleens of WT and ZEB1-TG mice injected with

AAV-shTGFBRII or AAV-control after tMCAO. After tMCAO,
although neutrophil infiltration into the brains of AAVshTGFBRII-transfected ZEB1-TG mice equaled that in AAVcontrol-transfected WT mice, neutrophil infiltration into the
brains of AAV-control-transfected ZEB1-TG mice was markedly reduced. AAV-shTGFBRII-transfected mice showed no
difference in the number of neutrophils, but AAV-controltransfected ZEB1-TG mice had greater neutrophil counts in
the spleen compared to AAV-control-transfected WT mice
(Figure 8G).
Confocal microscopy of immunofluorescent staining of
astrocytes showed that astrocytes from AAV-shTGFBRIItransfected WT and ZEB1-TG mice did not differ significantly in CXCL1 content. By contrast, astrocytes from
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Figure 7. Reduced Transmigration of Neutrophils in Astrocyte-Microglial Co-cultures from ZEB1-TG Mice
(A) General schematic of the Transwell system, with primary astrocytes alone or co-cultured with microglia.
(B) After astrocytes were isolated from WT and ZEB1-TG mice and exposed to OGD, neutrophil migration was measured by flow cytometry (FCM). CXCL1 in the
supernatant of astrocytes was also analyzed by ELISA.
(C) Microglia and astrocytes were co-cultured in the lower chamber of the Transwell system and exposed to OGD. Migration of neutrophils and CXCL1 in the
supernatant was measured by flow cytometry and ELISA, respectively.
(D) Procedure for the conditioned medium system of microglia and astrocytes. Microglia from both WT and ZEB1-TG mice were harvested and cultured for 12 hr
under OGD conditions. Conditioned medium was collected and added to the astrocytes for the next 12 hr. Expression of CXCL1 in astrocytes was measured by
flow cytometry and immunofluorescent staining.
(E) Expression of CXCL1 in astrocytes was examined by immunofluorescent staining and flow cytometry. Scale bars, 20 mm.
(F) Main cytokines produced by microglia that might affect CXCL1 expression were measured by qPCR.
(G) Antibodies against TNF-a, IL-4, IL-6, and TGF-b1 were added to the conditioned medium, and the migration of neutrophils was measured in the Transwell system.
(H) The mRNA of TGF-b1 after transfected with the ZEB1 expression or control plasmid.
(I) BV2 cells were co-transfected with the ZEB1 expression plasmid and different wild-type or truncated TGF-b1 promoter luciferase reporter constructs. Cellextract luciferase activities were determined 36 hr after transfection using a Betascope analyzer. Luciferase values were normalized to Renilla activities.
(J) Association of ZEB1 with the TGF-b1 promoter was analyzed by a quantitative ChiP assay.
Data indicate means ± SEM. *p < 0.05. See also Figures S7 and S8.

AAV-control-transfected ZEB1-TG mice showed significantly
less CXCL1 (Figure 8H). This suggests that microglial ZEB1
suppressed astrocytic CXCL1 secretion via the TGF-b1
signaling pathway.
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DISCUSSION
Because of the growing global incidence of ischemic stroke,
there is a compelling need to discover new ways to mitigate

Figure 8. Blocking TGF-BRII in Astrocytes Abolishes the Protective Effect of ZEB1 Overexpression in ZEB1-TG Mice
(A) Microglial TGF-b1 expression was tested by flow cytometry 1, 3, and 7 days after tMCAO and reperfusion in WT and ZEB1-TG mice.
(B) Statistical analysis of TGF-b1 expression.
(C and D) 24 hr after reperfusion, TGF-b1 and Iba-1 double-immunofluorescent staining was evaluated in brain sections from the penumbra of ischemic mice (D);
the graph shows relative intensities of TGF-b1 expression (C). Scale bar, 50 mm.
(E) Schematic map of the astrocyte-specific AAV-shTGFBRII.
(F) 24 hr after tMCAO, cells from the brain tissues underwent flow cytometry analysis. Histograms and quantification show expression of TGF-BRII in astrocytes
from AAV-shTGFBRII- or control AAV-transfected mice 24 hr after tMCAO.
(G) 24 hr after reperfusion, the number of neutrophils in the brains and spleens of WT and ZEB1-TG mice was measured by flow cytometry.
(H) Confocal microscopy images of anti-CXCL1/anti-GFAP double-immunostained astrocytes were used to measure astrocytic CXCL1 content (green indicates
GFAP; red indicates CXCL1, blue indicates nuclei stained with DAPI). Scalebar: 20 mm.
Data indicate means ± SEM; n = 6 per group. *p < 0.05.
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the disabling consequences of stroke. The immune system has
been consistently implicated in the pathophysiology of stroke
aftermath, and its activation is associated with unfavorable outcomes. In this study, we explored the contribution of a transcription factor, ZEB1, as a key molecular factor in regulating poststroke inflammatory events.
After ischemic insult to the CNS, excitotoxicity, calcium dysregulation, oxidative and nitrosative stress, and inflammation are
the most prominent processes leading to cell and tissue damage
in the ischemic tissue (Moskowitz et al., 2010). The potentially
salvageable tissue around the core of the ischemic tissue, referred
to as the penumbra, is a prime region to target. Our experiments
demonstrated that ZEB1 expression is elevated in the penumbra
under ischemic conditions, and elevated ZEB1 expression specifically localizes to microglia. The present experiments used conditional transgenic mice to determine whether ZEB1 specifically expressed in microglia is involved in the pathological immune
responses after ischemic stroke and, if so, to determine what
physiological role ZEB1 plays in post-ischemic responses.
To overcome the lack of specific tools to delineate the function
of microglia in pathophysiological processes, we used a genetic
tool that specifically and inducibly manipulated microglia by
invoking the expression of Cre recombinase driven by the
CX3CR1 promoter coupled with estrogen receptor. This technique takes advantage of microglia’s longevity and concomitant
self-renewal (Parkhurst et al., 2013; Wieghofer et al., 2015).
Although myeloid cells and microglia express CX3CR1 (White
and Greaves, 2012; Yona et al., 2013), there are many differences between these two cell types. Microglia are a self-renewing population with a low turnover rate (Ajami et al., 2007), while
myeloid cells (e.g., monocytes, dendritic cells, NK cells, and
T cells) will replenish with CX3CR1 bone marrow precursor
with a rapid turnover rate (Zhang et al., 2014; Arnold et al.,
2012). Based on these differences, we used CX3CR1CreER
mice to achieve selective genetic modification of microglia.
Four weeks after tamoxifen administration, Cre-dependent
modification of the gene was almost exclusively in microglia
(Parkhurst et al., 2013). In ZEB1-KD microglia, ZEB1 expression
was downregulated by approximately 50%. In ZEB1-KD mice,
the loxP site is located on one of the alleles. When loxP mice
were crossed with CX3CR1CreER mice, only one allele of zeb1
exon is cut away, and another allele could still express zeb1 (heterozygous). Thus, ZEB1 expression still occurred. ZEB1-TG
mice subjected to tMCAO had less severe brain injuries than
their WT controls. In a previous study of ischemic stroke, ZEB1
induction provided a protective response, since neurons from
ZEB1 / animals proved to be the more vulnerable to OGD
(Bui et al., 2009). This indicated that ZEB1 is a protective molecule that is expressed after ischemic stroke.
Microglia are so-called ‘‘housekeepers’’ of the brain, constantly ‘‘surveying’’ the local microenvironment, maintaining
brain homeostasis, and responding to injury by extending or retracting their filopodia-like protrusions (Benarroch, 2013; Nimmerjahn et al., 2005). The ramified shape of microglia determines
its function. Our morphological analyses showed that there are
more ramified microglia with more complex processes and
branches in ZEB1-TG mice. Microglial processes are like ‘‘sensors’’ of the brain microenvironment. The increased complexity
3584 Cell Reports 22, 3574–3586, March 27, 2018

of microglia processes in ZEB1-TG microglia may enable them
to react more accurately and quickly to a stimulus. According
to the gene array data, the terms affected by ZEB1 focus on immune system process and innate immune response. This confirms that microglial ZEB1 expression is involved in pathological
immune responses following ischemic stroke.
The immune system participates in all stages in the aftermath
of ischemic stroke, from the damage events to the regeneration
processes (Iadecola and Anrather, 2011). In this context, reduced
immune cell infiltration in the ZEB1-TG group in comparison with
the WT group and neutrophils displayed the most obvious
change. Neutrophils are known as crucial players during acute
inflammation (Mantovani et al., 2011), and as pivotal immune
components after ischemic stroke, neutrophils are one of the first
cell types contributing to BBB disruption, edema, and neuronal
death (Buck et al., 2008; Jickling et al., 2015). Infiltration of neutrophils into the ischemic area continues only 30 min post-stroke to
several hours after ischemia peaks at 24–48 hr and then decline
(Koh et al., 2015). Infiltrating neutrophils produce reactive oxygen
species, cytokines, and metalloproteases, which aggravate tissue damage (Galli et al., 2011). The recruitment of neutrophils
into tissue is orchestrated by tissue-resident cells, which could
release multiple chemokines or adhesion molecules (Gelderblom
et al., 2012; Kim and Luster, 2015; Strecker et al., 2017). In the
CNS, astrocytes are the major source of CXCL1 in multiple animal
models (Gelderblom et al., 2012; Rubio and Sanz-Rodriguez,
2007; Xu et al., 2014), which our results also confirmed. However,
when we spatially separated astrocytes and neutrophils from
either WT or ZEB1-TG mice that were cultured for 12 hr under
OGD conditions, the migration index of neutrophils was similar
for the two groups. Taken together, this suggests that in situ microglia might have been influencing the expression of CXCL1 in
astrocytes. When we cultured astrocytes with ZEB1-TG microglia-conditioned medium, we discovered that CXCL1 was
reduced compared with astrocytes alone; co-culture with WT microglia was similar. This suggests that ZEB1-TG microglia could
regulate CXCL1 production in astrocytes.
With mammary carcinomas, TGF-b1 signaling can mediate the
stromal-epithelial and host tumor interaction by regulating the
expression of CXCL1 (Novitskiy et al., 2011). In the CNS,
TGF-b1 is expressed primarily by microglia and, in association
with invading macrophages, contributes to various forms of tissue damage (Kiefer et al., 1995; Lehrmann et al., 1995). On this
basis, we reasoned that microglia and astrocytes might interact
through the TGF-b1 pathway. The higher concentration of
TGF-b1 in ZEB1-TG microglia might also explain why ZEB1-TG
microglia maintain a less activated state after ischemic stroke
(Butovsky et al., 2014). In this context, our overall results suggest
that ZEB1 in microglia could affect the infiltration of neutrophils
into the ischemic brain by regulating CXCL1 production in astrocytes through TGF-bRII. TGF-b1 is a prominent cytokine after
stroke, reducing glial activation, suppressing the release of
harmful oxygen- and nitrogen-derived products, and promoting
angiogenesis in the penumbral area. On the other hand, TGF-b1
stimulates glial scar formation and amyloid production, which
can lead to a higher risk of cognitive deficit (Ceulemans et al.,
2010). Our experiment demonstrated another anti-inflammatory
role of TGF-b1 during ischemic stroke. In the mouse TGF-b1

promoter region, there are three E2-box motifs for ZEB1 binding.
Our promoter-reporter assay and ChIP assay results indicated
that ZEB1 binds directly to the endogenous TGF-b1 promoter,
resulting in the transcriptional activation of TGF-b1.
In summary, we revealed that ZEB1 is a key molecule in the
regulation of microglia responses after brain ischemia. Its activity
manifested through CNS microglia ameliorated the inflammatory
burden after stroke by reducing the infiltration of neutrophils into
CNS. This reduction is directly mediated by astrocytes through
TGF-b1 signaling. Further understanding of ZEB1 function will
aid in understanding how microglia contribute to the development
of ischemic stroke. Manipulation of ZEB1 may provide a therapeutic opportunity for mitigating the consequences of ischemic
stroke through modulation of microglia-mediated inflammation.
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EXPERIMENTAL PROCEDURES
Mice
Mice carrying ZEB1-floxed alleles (Zeb1-TG and Zeb1-KD mice) were a gift
from Dr. Shuang Yang, and CX3CR1CreER mice were purchased from The
Jackson Laboratory (#021160; Bar Harbor, ME, USA). For in vivo and in vitro
experiments, 8-week-old male C57BL/6 mice and neonatal mice were used.
All animal procedures were approved by the Animal Experiments Ethical
Committee of Tianjin Medical University General Hospital.
Induction of Focal Cerebral Ischemia and Neurobehavioral Testing
Focal cerebral ischemia was modeled by inducing left-side tMCAO, based on
the methods described by Longa et al. (1989). Then, neurological function was
evaluated in each group of mice after tMCAO by using the mNSS, adhesiveremoval test, foot-fault test, and corner-turning test (Li et al., 2017).
PCR
cDNA was prepared from cells or indicated tissues; primers are displayed in
Tables S1, S2, and S3.
Immunohistochemistry
Immunohistochemistry staining was conducted as previously described (Li
et al., 2017). See also the Supplemental Experimental Procedures.
Flow Cytometry
Single-cell suspensions were prepared from spleen or brain tissues and
stained with fluorochrome-conjugated antibodies; more detailed information
is given in the Supplemental Experimental Procedures.
In Vitro Cell Culture and Migratory Assay
Cells that were isolated were cultured under indicated conditions for migration
as described previously (Jiang et al., 2017).
Statistics
Statistical analyses were performed using GraphPad Prism software. Differences were considered significant at p < 0.05. The Mann-Whitney U test
was used to compare differences between groups. A one-way ANOVA followed by a Tukey post hoc test was used for three or more groups. Data are
expressed as mean ± SEM.
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